Kaleidoscope Bio

Kaleidoscope Bio develops a software platform for orchestrating research and development work across internal teams and external partners such as CROs and CDMOs. The product is modular: customers can adopt individual capabilities or run an end-to-end platform. Advertised modules include request management, CRO/CDMO collaboration with granular permissions, status tracking of compound work, an assay catalog with templatized result tables and metadata, an entity/compound registry spanning modalities, connected inventory management, ELN/LIMS data capture, summary dashboards, design-make-test-analyze (DMTA) cycle management, and logic-driven assay cascades.

The platform is positioned around decision-making and program visibility rather than only data recording: features include assay status boards, synthesis selection with voting and commenting, design cycle tracking through custom workflow stages, entity comparison across experiments and batches, cohort and experiment summaries, program timelines measured against top-down plans, and decision summaries that pin the underlying data. It offers programmatic access via an API and Python client, automation triggers, and role-based access control, and integrates with existing life science tools and databases via automated sync, API, or configurable triggers so customers do not have to migrate data.

An investor spotlight published by OMERS Ventures frames Kaleidoscope as building an R&D operations platform purpose-built for biotech, intended to sit alongside electronic lab notebooks as the layer where R&D decisions are made and collaborative work is actioned, addressing inconsistently formatted data spread across disparate systems, limited program visibility, duplicative experiments, and reliance on PowerPoints, emails and meetings for status reporting.

Business model

B2B SaaS software sold to life science R&D organizations, with standard multi-tenant, single-tenant, and on-premises deployment options.

Traction

Customer testimonials on the company site cite reductions in time spent collating data (one director reports roughly 3x less time weekly searching for and navigating data, and one workflow reduced from 4-5 steps to one) and time savings of 10 or more hours per week; named users include representatives of PsiThera and other therapeutics companies. Marketed outcome claims include reaching IND more than a year faster and saving over $1M per year in FTE costs.

Latest developments

In December 2024, OMERS Ventures published a spotlight on the company based on conversations with co-founder and CEO Bogdan Knezevic, describing its R&D operations platform and roadmap ambitions including automating downstream data-intensive processes such as IND submission and patent filing drafting.